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ABSTRACT
Point-of-care (POC) tests are becoming more available, although the way in which they should be used
is currently undecided. Any ‘laboratory’-based diagnosis of respiratory infections has three components:
the specimen taken, the test used, and the interpretation of the results. Each of these components needs
to be carefully addressed when using POC tests for the diagnosis of respiratory tract infections. Given
the enthusiasm with which POC tests are being developed, it is likely that they will be used more and
more widely. If so, the advantages and limitations of their use should be fully discussed and the
implications recognised.
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In this issue of CMI, Weitzel and colleagues from
Berlin present data concerning the use of a point-
of-care (POC) test for the detection of inﬂuenza A
and B viruses [1]. This and other similar tests are
intended to be used by clinicians at the bedside to
allow patient management and treatment deci-
sions to be made very rapidly, especially with
respect to returning travellers who may be carry-
ing, e.g., new pathogenic strains of pandemic
inﬂuenza virus. The test evaluated by Weitzel
et al. [1] shows adequate speciﬁcity (the positives
were, except for a small number, correct with only
one false-positive) for both viruses, but the sen-
sitivity was low. Only about two-thirds of the
individuals who were positive according to PCR
assays or culture were positive according to the
POC test. This is worrying if this and other similar
tests (http://www.who.int/csr/disease/avian_
inﬂuenza/guidelines/rapid_testing/en) are pro-
moted for widespread use as front-line tests for
identifying inﬂuenza in febrile travellers return-
ing from foreign countries, which is an approach
that has been recommended by the WHO (http://
www.who.int/csr/disease/avian_inﬂuenza/guide
lines/rapid_testing/en).
Any ‘laboratory-based’ diagnosis of respiratory
infections, bedside or otherwise, has three com-
ponents: the specimen taken from the patient; the
test used; and the interpretation of the result of
the test. All these components must be of a
standard good enough for the task, but the quality
of the specimen is crucial. A poorly taken speci-
men containing no or insufﬁcient virus material
cannot yield a positive result, even if the patient
is, indeed, infected. Inevitably, such a specimen
will give a false-negative result. Where the
patient may be bringing a novel infection into a
country or community, this is potentially disas-
trous and negates the purpose of using a POC
test.
All diagnostic virologists are aware of the
difﬁculties of getting good respiratory specimens.
As few patients enjoy having swabs or aspirators
inserted into their nose or nasopharynx, it is
much, much easier to take a bad specimen than a
good one. Missing from almost all tests, POC or
traditional, is any form of marker to indicate
whether the specimen contains sufﬁcient material
to make the result reliable, particularly when
apparently negative results are obtained. Only
immunoﬂuorescence (IF) provides this vital feed-
back at present [2]—if there are no ciliated
respiratory cells visible in the preparation exam-
ined in the microscope, the microscopist knows
that the specimen is unsuitable, either because it
has been inadequately taken or because it has
been mishandled during preparation. POC tests
have no such safeguard, and the poor sensitivity
reported by Weitzel et al. [1] may have been
caused, at least in part, by poor specimens having
been taken. Tellingly, the authors comment that
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the positivity rate was higher with more ﬂoridly
ill patients and with children, from both of whom
it may have been easier to get a competent
specimen.
This is not a transient problem. Diagnostic
virologists know that getting good, consistent
respiratory specimens is a battle that is never
won. Non-virologists rarely understand the prob-
lem in detail, and the continuing successful
collection of specimens at the bedside relies
heavily on (often indignant) feedback from the
laboratory. Moreover, no sooner is one set of
nurses or junior doctors well-trained in how to
collect a good specimen than staff rotation takes
the situation back to square one. Commercially
produced tests have not hitherto included a
marker to assess specimen quality, and perhaps
the manufacturers should be more aware of this
deﬁciency. It does not matter how well the actual
test performs if it does not tell the user that time is
being wasted on a useless specimen, and that the
ensuing result (if negative) cannot be relied upon.
Dipstick-type tests have been available to detect
protein, sugar, haemoglobin, etc. in urine for
many years. In contrast to respiratory tract spec-
imens, urine is (comparatively speaking) easy to
collect and much more standard than the respir-
atory equivalents—if it looks like and smells like
urine, that is what it is likely to be. A swab, or
even an aspirate, is not so informative, and the
available quantity is much smaller. Bacteriological
swabs are less critical because culture is relatively
fast and can compensate better for a minimal
specimen.
Another limitation of the speciﬁc POC test
evaluated by Weitzel et al. [1] is that, at present, it
detects only inﬂuenza A or B viruses; other
viruses also cause very similar syndromes [3].
The ability to detect a different aetiological cause
(because dual infections are generally rare, at least
in adults) is more useful than a test that is simply
negative for inﬂuenza. Not inﬂuenza virus? Then
what is the patient suffering from? Any test that
concentrates on one virus to the exclusion of
others must give a biased perspective on virus
diseases generally. It may not be inﬂuenza virus,
but it could be SARS virus, an adenovirus, a
parainﬂuenza virus, a respiratory syncytial virus,
a metapneumovirus, or even measles virus. Not
to mention a common cold virus.
Finally, there is the matter of interpreting (any
and all) results and assessing new tests and
variants of old tests. This is, or has been, the
province of the professional virologist (http://
www.rcpath.org/index.asp?PageID = 117). Train-
ing to become proﬁcient takes time and experi-
ence; are those clinicians who might use POC
tests willing to acquire a similar proﬁciency in
virology, as well as in their own clinical specialty?
In English, this is called ‘keeping a dog and
barking yourself’. Does it make sense? Both a
positive result and a negative result need inter-
pretation, and even positive results are not always
signiﬁcant [4–10]. This should be a task for an
individual who is familiar not only with the test
being used, and its limitations, but also with
whatever other viruses are currently circulating in
the community ⁄world at large, as well as the
medical details of the patient; in other words,
someone who can put the result into a wider and
proper context.
Given the enthusiasm with which POC tests are
being developed, it is likely that they will be used
more and more widely. If so, the advantages and
limitations of their use should be fully discussed
and the implications recognised.
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